Vera initiates Phase 3 study for kidney disease therapy atacicept
peterschreiber.media
Vera Therapeutics (NASDAQ:VERA) has initiated a pivotal Phase 3 study of its drug candidate atacicept for the treatment of IgA nephropathy, an autoimmune kidney disorder also known as Berger's disease.
The company will be testing the therapy on IgA nephropathy patients with persistent proteinuria who are at high risk of the disease progressing despite ACEi or ARB therapy.
Vera plans to present results from a Phase 2b study for the drug at the 60th European Renal Association Congress in June.